Michael G. Kauffman

2021

In 2021, Michael G. Kauffman earned a total compensation of $3.1M as Senior Clinical Advisor and Former Chief Executive Officer at Karyopharm Therapeutics, a 22% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$237,188
Option Awards$1,507,217
Salary$474,375
Stock Awards$832,832
Other$17,977
Total$3,069,589

Kauffman received $1.5M in option awards, accounting for 49% of the total pay in 2021.

Kauffman also received $237.2K in non-equity incentive plan, $474.4K in salary, $832.8K in stock awards and $18K in other compensation.

Rankings

In 2021, Michael G. Kauffman's compensation ranked 4,338th out of 12,415 executives tracked by ExecPay. In other words, Kauffman earned more than 65.1% of executives.

ClassificationRankingPercentile
All
4,338
out of 12,415
65th
Division
Manufacturing
1,789
out of 5,505
68th
Major group
Chemicals And Allied Products
753
out of 2,375
68th
Industry group
Drugs
672
out of 2,096
68th
Industry
Pharmaceutical Preparations
477
out of 1,546
69th
Source: SEC filing on April 8, 2022.

Kauffman's colleagues

We found five more compensation records of executives who worked with Michael G. Kauffman at Karyopharm Therapeutics in 2021.

2021

Richard Paulson

Karyopharm Therapeutics

Chief Executive Officer

2021

Sharon Shacham

Karyopharm Therapeutics

Chief Scientific Officer

2021

Michael Mason

Karyopharm Therapeutics

Chief Financial Officer

2021

Jatin Shah

Karyopharm Therapeutics

Chief Medical Officer

2021

Ran Frenkel

Karyopharm Therapeutics

Executive Vice President, Chief Development Officer

News

You may also like